The first research was published in 1993 and since then many papers have appeared indicating GcMAF cured Cancer and eradicated HIV by simply activating the immune system.
Hundreds of scientists have worked on this and related projects, but studies are still only small scale and the researchers are not making GcMAF available to the public. Part of the problem is that the most visible researcher, Dr. Nobuto Yamamoto in Philadelphia USA, filed a GcMAF patent and that seems to have scared most off.
In our research section, we have compiled an overview of published research. Feel free to browse and look for more information elsewhere. Please read our Controversy reports for more information as to why GcMAF is not available for the public. A handful of cancer clinics do use GcMAF.
How does it work?
In a healthy person macrophages in our bloodstream scour our bodies and kill malignancies; they get the message to go on the attack from Gc MAF, which is converted from Gc Protein. But malignant cells like cancer send out an enzyme called Nagalase that stops conversion of Gc protein to Gc MAF (Macrophage Activating Factor); so the macrophages never get the message to go into action – in this way cancer suppresses the immune system, and cancer cells grow unchecked. Research indicates it works the same way with HIV.
A precis of the process is to extract Gc Protein from blood; modify it outside the body to become the missing Gc-MAF, and inject it once a week for 22 weeks. (Some encapsulated tumours require additional treatment. Some types of cancer may require longer treatment.)
Activated macrophages also reverse other diseases that attack the immune system. Therefore GcMAF is not only a potential treatment for Cancer but also for conditions like Osteoporosis, Aids, Hodgkin’s, Lupus, MS, Fibromyalgia, Parkinson’s, various bacterial and viral infections and various types of Immune dysfunction.
Small trials to build the case are now taking place in Belgium, The Netherlands and the UK.
Patients diagnosed with any of these illnesses or who are otherwise convinced of the benefits of GcMAF for their health and who have done their own research on it are invited to respond. To assist the project we would appreciate receiving a copy of diagnostic information and update reports from a physician during and after treatments, to help build the case that GcMAF is a cure for various illnesses, which will help to make it available to the public. Participants are free to stop at any time.
If you as a patient are interested in GcMAF, and you live within the geographical triangle of Rotterdam, Brussels and London, please feel free to contact us.
